Fig. 7
Heterogeneities of drug sensitivity and immunotherapy response in URGsig-based subgroups. (A) Lollipop plot displaying the relationships between the risk scores and drug sensitivity in TCGA-LAML cohort. The color of the lollipop indicates whether the risk scores are related to drug resistance (red) or drug sensitivity (blue). (B–G) Comparisons of predicted IC50 of commonly used drugs between the low-risk (n = 66) and high-risk (n = 66) patients in TCGA-LAML cohort. (H) Comparison of the URGsig-risk scores between complete-remission patients (n = 115) and refractory patients (n = 47) in Beat AML cohort. (I) Comparison of the URGsig-risk scores between newly-diagnosed patients (n = 10) and relapsed patients (n = 10) in GSE66525 cohort. (J) TIDE analysis predicting the difference of response to immunotherapy between the two risk subgroups in TCGA-LAML cohort. (K) Submap analysis predicting the difference of response to anti-PD1 and anti-CTLA4 immunotherapy in the two risk subgroups in TCGA-LAML cohort. *p < 0.05, **p < 0.01, *** p < 0.001, **** p < 0.0001. nhigh-risk = 66 and nlow-risk = 66 in TCGA-LAML cohort.
